
- GMP
About
ReiThera develops and manufactures viral-vector-based genetic vaccines and advanced therapies. It supports biotech and pharmaceutical programs from early research through clinical and commercial readiness, with sites in Rome and Naples, Italy.
Services
Technology Development
Transforms nucleotide or amino acid sequences and early-stage concepts into functional viral vectors for research, pre-GMP development, or GMP manufacturing.
Vector engineering
Designs, engineers, optimizes, and characterizes viral vectors for vaccines and advanced therapies.
Plasmid design and sequence assembly
Provides codon optimization, transgene design, plasmid construction, and sequence assembly for vector programs.
Recombinant seed generation
Creates recombinant seed material for viral vector development.
R&D-grade vector production
Produces vectors at research grade for early development work.
Pre-GMP seed production
Generates seed material intended for pre-GMP development workflows.
Analytical method development
Develops fit-for-purpose analytical methods and customized analytical strategies for vector programs.
Process Development
Designs and optimizes upstream and downstream workflows for scalable viral vector manufacturing.
GMP Manufacturing
Manufactures viral vectors and ATMPs under GMP for clinical development and commercial production.
Aseptic fill-finish
Provides aseptic filling in EC Grade B facilities with automated and manual options.
Quality System
Supports development and manufacturing under an integrated quality system.
Analytics
Provides analytical development integrated with process development, manufacturing, and quality functions.
- Turnaround
- Rapid vector development
Capabilities
- Assays and studies
- AAV · Process development · HEK293 · Bioreactors · Fill-finish · Analytical method development · Fit-for-purpose analytical methods · Batch release · In-process control
- Scale and capacity
- 2,000 L bioreactor capacity · 870 m² GMP production suites · 400 m² quality control laboratories · 3,470 m² total area · 1,500 m² newly validated expansion area · Up to 2 L bulk independent small-scale production area · Up to 30 m² cultivation area · Up to 3,500 vials per batch
- Therapeutic areas
- Infectious diseases · Oncology · Personalized medicine · Cancer immunotherapy
Instruments and platforms
- 2,000 L bioreactors
- 200 L disposable stirred-tank bioreactors
- 1,000 L disposable stirred-tank bioreactors
- 2,000 L disposable stirred-tank bioreactors
- Fixed-bed bioreactors
- WAVE bioreactors
- oRABS Isolator System
- Watson-Marlow Flexicon FCP50W Automated Filler
Modalities and species
- Modalities
- Antibody · Viral vector · Vaccine · Plasmid DNA
- Species and models
- HEK293 · Duck Embryo Fibroblast-derived production platform · Gorilla adenovirus · Chimpanzee-derived adenovirus (ChAd)
Certifications
As the company states them, with the certificate or registry record where there is one.
GMPSelf-reported
As listed: GMP-certified facility; cGMP production suites
Company
- Type
- CRDMO
Locations
- Based in
- Rome, Italy
- Sites
- Rome, Italy · Naples, Italy
Contacts
- General enquiry
- info@reithera.com on their site
Public records
- Parent company
- REITHERA S.R.L. · IT GLEIF
Similar labs
Work here? Claim this listing